Ultragenyx Pharmaceutical-Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx (RARE) came out with a quarterly loss of $1.52 per share versus the Zacks Consensus Estimate of a loss of$ 1.64. This compares to loss of $2.25 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 7.32%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 1.72 per share when it actually produced a loss of $2.03, delivering a surprise of -18.02%. Over the last four quarters, the company h ...